ABSTRACT
Purpose: To compare the efficacy of infliximab and adalimumab in patients with refractory uveitis-related macular edema (ME).
Methods: A retrospective study was conducted in all patients with refractory uveitis-related ME treated with infliximab or adalimumab in Pitié-Salpêtrière hospital between January 1, 2006 and January 1, 2016. All patients underwent a complete ophthalmologic examination, OCT and retinal angiography at baseline, and 6 (M6) and 24 months (M24) after treatment initiation. Main outcome was a decrease in central foveal thickness (CFT) on OCT.
Results: Twenty-five patients were included: 12 treated with adalimumab and 13 treated with infliximab. The median baseline CFT was 381 μm (Q1 = 254; Q3 = 470) in the adalimumab group and 469 μm (307; 539) in the infliximab group. At M6, 6/12 adalimumab-treated patients (50%) and 8/13 infliximab-treated patients (61%) were responders. The median CFT decrease from baseline was 61 μm (17–136) and 66 μm (−59–119) respectively at M6 and M24 in the adalimumab group versus 92 μm (9–165) and 52 μm (33–130) respectively at M6 and M24 in the infliximab group (all p > 0.05).
Conclusion: No significant difference in efficacy was observed between infliximab and adalimumab at M6 and M24.
DECLARATION OF INTEREST
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.